GFAP与UCHL-1生物标志物在高危轻度创伤性脑损伤中的预后价值:一项关于短期与长期结局的前瞻性纵向研究
这项前瞻性单中心研究纳入441例≥18岁、GCS≥13、伤后24小时内就诊且因使用抗凝/抗血小板药物被视为颅内出血高风险的mTBI患者,急诊入院时行首次头颅CT和血清GFAP、UCHL-1采样,24小时复查CT,并在3个月和6个月用RPQ评估脑震荡后症状。75例(17%)首次CT阳性;GFAP>30 pg/ml、UCHL-1>360 pg/ml及两者联合升高与CT异常强相关,敏感度96%(95%CI 88.8-99.2)、NPV 96%(95%CI 90.6-98.9),特异性仅24%(95%CI 20-29)。366例基线CT阴性者中仅3例(0.82%)发生迟发性颅内出血,入院时生物标志物阴性者无一发生迟发性出血。随访时15-22%患者报告持续性轻度脑震荡后症状,基线生物标志物、临床特征及影像均无显著预测价值。
要点
- 在高危mTBI(GCS≥13、伤后24小时内、使用抗凝/抗血小板药)患者中,GFAP>30 pg/ml、UCHL-1>360 pg/ml及两者联合升高检测急性颅内病变的敏感度为96%(95%CI 88.8-99.2)、NPV为96%(95%CI 90.6-98.9),特异性仅24%(95%CI 20-29)。
- 366例初始CT阴性的高危mTBI患者中,迟发性颅内出血仅3例(0.82%);入院时生物标志物阴性者无一例发生迟发性颅内出血。
- 随访时15-22%患者报告持续性轻度脑震荡后症状,基线生物标志物、临床特征及影像学表现均无显著预测价值。
- 作者认为GFAP和UCHL-1对急性颅内病变敏感度优异,可能支持急诊更安全、更有选择性地使用CT;初始CT阴性后迟发性出血发生率低,提示常规复查影像可能不必要,尤其入院生物标志物阴性时。
- 作者指出持续性脑震荡后症状仍常见且不可预测,强调需要超越现有生物标志物的更好预后工具。
适用人群与场景
- 成人(≥18岁)轻度创伤性脑损伤患者,格拉斯哥昏迷评分≥13,伤后24小时内就诊于急诊科。
- 所有患者因使用血液稀释剂(抗凝/抗血小板药物)被视为颅内出血高风险。
诊断标准与关键阈值
- 轻度创伤性脑损伤定义:格拉斯哥昏迷评分≥13。
- 急性颅内病变的生物标志物阈值:GFAP>30 pg/ml、UCHL-1>360 pg/ml,或两者联合升高。
- 脑震荡后症状评估:使用Rivermead脑震荡后症状问卷(RPQ)在3个月和6个月评估;症状状态定义为相对于伤前基线有临床显著恶化。
处置流程与药物剂量
- 急诊入院时行首次头颅CT并采集血清生物标志物样本。
- 24小时复查头颅CT以检测迟发性颅内出血。
研究设计与关键结果
- 研究类型:前瞻性、单中心纵向研究;共441例符合纳入标准并入选。
- 75例(17%)首次CT阳性;这些患者年龄显著更大且高血压更常见,其他临床和实验室参数无显著差异。
- GFAP>30 pg/ml、UCHL-1>360 pg/ml及两者联合升高与CT异常强相关,敏感度96%(95%CI 88.8-99.2)、NPV 96%(95%CI 90.6-98.9)、特异性24%(95%CI 20-29)。
- 366例基线CT阴性患者中,迟发性颅内出血仅3例(0.82%);入院时生物标志物阴性者无一例发生迟发性颅内出血。
- 随访时15-22%患者报告持续性轻度脑震荡后症状,基线生物标志物、临床特征及影像学表现均无显著预测价值。
证据类型、等级与局限
- 证据类型:前瞻性纵向研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为GFAP和UCHL-1对急性颅内病变显示优异敏感度,可能支持急诊更安全、更有选择性地使用CT成像。
- 作者认为初始CT阴性后迟发性出血发生率低,提示高危mTBI患者常规复查影像可能不必要,尤其在入院生物标志物阴性时。
- 作者指出持续性脑震荡后症状仍常见且不可预测,强调需要超越现有生物标志物的更好预后工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Blood biomarkers such as glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) have been shown to rise after mild traumatic brain injury, improving early detection of intracranial lesions. However, evidence on their role in detecting delayed intracranial hemorrhage, especially in patients on anticoagulants, and on their ability to predict long-term post-concussive symptoms is still limited and remains largely unexplored. Our study is the first to address this gap, evaluating these biomarkers for early detection of delayed bleeding and their association with symptom persistence at 3 and 6 months.
OBJECTIVE: To investigate the diagnostic and prognostic utility of serum biomarkers GFAP and UCH-L1 in adult patients with mild traumatic brain injury (mTBI), focusing on their association with delayed intracranial hemorrhage and post-concussive symptoms at 3 and 6 months.
METHODS: This prospective, single-center study enrolled adult patients (≥18 years) with mTBI (Glasgow Coma Scale ≥13) presenting within 24 h of injury. All patients were considered at high risk for intracranial bleeding due to blood thinners. Initial head CT and serum biomarker sampling were performed upon emergency department (ED) admission, followed by repeated CT imaging at 24 h. Serum GFAP and UCH-L1 levels were analyzed for their sensitivity and negative predictive value (NPV) in detecting acute and delayed intracranial injury, and for their association with post-concussive symptoms (PCS) assessed at 3 and 6 months using the Rivermead Post-Concussion Symptoms Questionnaire (RPQ). Symptomatic status was defined by clinically significant worsening relative to the pre-injury baseline.
RESULTS: Overall, 441 patients fulfilled the inclusion criteria and were enrolled. Seventy-five patients (17 %) had positive findings on initial CT. These individuals were significantly older and more frequently hypertensive, while other clinical and laboratory parameters showed no significant differences. GFAP levels >30 pg/ml, and UCH-L1 > 360 pg/ml, and combined GFAP/UCH-L1 elevation were strongly associated with CT abnormalities, yielding high sensitivity (96 %; 95 % CI: 88.8-99.2) and NPV (96 %; 95 % CI: 90.6-98.9), though specificity was limited (24 %; 95 % CI: 20-29). Among 366 patients with negative baseline CTs, delayed intracranial hemorrhage occurred in only 3 cases (0.82 %). None of the patients with negative biomarker results at admission developed delayed intracranial hemorrhage. At follow-up, 15-22 % of patients reported persistent mild PCS, with no significant predictive value from baseline biomarkers, clinical features, or imaging findings.
CONCLUSION: GFAP and UCH-L1 demonstrate excellent sensitivity for detecting acute intracranial lesions in mTBI and may support safer, more selective use of CT imaging in the ED. The low incidence of delayed hemorrhage following a negative initial CT suggests that routine repeat imaging may be unnecessary in mTBI patients, particularly in the case of negative biomarkers at admission. However, persistent post-concussive symptoms remain common and unpredictable, underscoring the need for improved prognostic tools beyond current biomarkers.
TRIAL REGISTRATION: ClinicalTrials.govNCT06069674.
参考来源
- Spaziani G, Rozzi G, Baroni S, et al. Prognostic value of GFAP and UCHL-1 biomarkers in high-risk mild traumatic brain injury: A prospective longitudinal study of short- and long-term outcomes. Am J Emerg Med. 2025. PMID: 41455435. doi:10.1016/j.ajem.2025.12.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。